2022
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnel
2021
Long-Term Complications in Youth-Onset Type 2 Diabetes
Bjornstad P, Drews K, Caprio S, Gubitosi-Klug R, Nathan D, Tesfaldet B, Tryggestad J, White N, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. New England Journal Of Medicine 2021, 385: 416-426. PMID: 34320286, PMCID: PMC8697255, DOI: 10.1056/nejmoa2100165.Peer-Reviewed Original ResearchConceptsType 2 diabetesDiabetic kidney diseaseNerve diseaseKidney diseaseRetinal diseasesYouth-Onset Type 2Minority raceDevelopment of complicationsIncidence of dyslipidemiaRisk of complicationsMulticenter clinical trialDiagnosis of diabetesMicrovascular complicationsAdverse eventsCumulative incidenceTerm complicationsGlycemic controlRelated complicationsObservational followMean ageRisk factorsClinical trialsComplicationsDyslipidemiaHypertension
2017
Management and Family Burdens Endorsed by Parents of Youth <7 Years Old With Type 1 Diabetes
Harrington KR, Boyle CT, Miller KM, Hilliard ME, Anderson BJ, Van Name M, DiMeglio LA, Laffel LM. Management and Family Burdens Endorsed by Parents of Youth <7 Years Old With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2017, 11: 980-987. PMID: 28770627, PMCID: PMC5951003, DOI: 10.1177/1932296817721938.Peer-Reviewed Original ResearchConceptsType 1 diabetesDiabetes managementT1D Exchange Clinic RegistryDuration of diabetesMean hemoglobin A1cFamily impact scoresLow blood sugarQuality of sleepYoung childrenMedical record informationClinical characteristicsHemoglobin A1cSerious complicationsBlood sugarClinic registryMean ageFamily burdenSubstantial burdenParental burdenDiabetesAge groupsInsulin pumpType 1Parents of youthChildren's diabetes management